Polysubstance use patterns and novel synthetics: A cluster analysis from three U.S. cities


Autoři: Luther Elliott aff001;  Christopher Keith Haddock aff002;  Stephanie Campos aff003;  Ellen Benoit aff004
Působiště autorů: New York University, College of Global Public Health, Center for Drug Use and HIV/HCV Research, New York, New York, United States of America aff001;  National Development and Research Institutes—USA, Leawood, Kansas, United States of America aff002;  New York State Psychiatric Institute, Columbia University, New York, New York, United States of America aff003;  North Jersey Community Research Initiative, Research Division, Newark, New Jersey, United States of America aff004
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225273

Souhrn

The rapid emergence of novel psychoactive substances within the past decade has raised new concerns about the harms associated with unregulated drug use. Synthetic analogues—chemically related to established psychoactive substances like cannabis sativa and catha edulis—in particular have proliferated rapidly, allowing little opportunity for scientific research or the establishment of informal guidelines for safe use among consumers. To explore how synthetic substance use relates to other forms of use, this paper presents an analysis of polysubstance use among a sample of 676 people who use illicit substances in the United States. Participants were sampled from three greater metropolitan areas (Houston/Galveston, Texas; New York City; and New Orleans, Louisiana). Study researchers used cluster-type analyses to develop dendrogram visualizations of the interrelationships between substance types. Results suggest a considerable variation in substance and polysubstance use patterns across states in the U.S. Polysubstance use clustered around well-observed combinations like MDMA/cannabis and cocaine/heroin. Synthetic cannabinoids and cathinones showed no strong clustering with other substances. High rates of binge drinking among users of other substances further support the importance of interventions sensitive to the clinical challenges of polysubstance use.

Klíčová slova:

Alcohol consumption – Cannabinoids – Cannabis – Cocaine – Drug research and development – Drug users – Heroin – Drug synthesis


Zdroje

1. Conway KP, Vullo GC, Nichter B, Wang J, Compton WM, Iannotti RJ, et al. Prevalence and patterns of polysubstance use in a nationally representative sample of 10th graders in the United States. Journal of Adolescent Health. 2013;52(6):716–23. doi: 10.1016/j.jadohealth.2012.12.006 23465320

2. Moss HB, Chen CM, Yi H-y. Early adolescent patterns of alcohol, cigarettes, and marijuana polysubstance use and young adult substance use outcomes in a nationally representative sample. Drug and alcohol dependence. 2014;136:51–62. doi: 10.1016/j.drugalcdep.2013.12.011 24434016

3. Connor JP, Gullo MJ, White A, Kelly AB. Polysubstance use: diagnostic challenges, patterns of use and health. Current opinion in psychiatry. 2014;27(4):269–75. doi: 10.1097/YCO.0000000000000069 24852056

4. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94(7):961–72. 10707430

5. Tunnicliff G. Sites of action of gamma-hydroxybutyrate (GHB)–a neuroactive drug with abuse potential. Journal of Toxicology: Clinical Toxicology. 1997;35(6):581–90. doi: 10.3109/15563659709001236 9365423

6. Galloway GP, Frederick S, Staggers FE, Gonzales M, Stalcup SA, Smith DE. Gamma‐hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction. 1997;92(1):89–96. 9060200

7. Miotto JD, Basch Janice, Murray Shanna, Zogg Jennifer, Rawson Richard, Karen, Miotto K, Darakjian J, Basch J, Murray S, Zogg J, et al. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. American Journal on Addictions. 2001;10(3):232–41. doi: 10.1080/105504901750532111 11579621

8. Chin RL, Sporer KA, Cullison B, Dyer JE, Wu TD. Clinical course of γ-hydroxybutyrate overdose. Annals of Emergency Medicine. 1998;31(6):716–22.

9. Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. Journal of Psychoactive Drugs. 1998;30(4):367–9. doi: 10.1080/02791072.1998.10399712 9924842

10. Smilkstein MJ, Smolinske SC, Rumack BH. A case of MAO inhibitor/MDMA interaction: agony after ecstasy. Journal of Toxicology: Clinical Toxicology. 1987;25(1–2):149–59. doi: 10.3109/15563658708992620 2884326

11. Dowling GP. Human deaths and toxic reactions attributed to MDMA and MDEA. Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA: Springer; 1990. p. 63–75.

12. Hearn WL, Flynn DD, Hime GW, Rose S, Cofino JC, Mantero‐Atienza E, et al. Cocaethylene: a unique cocaine metabolite displays high affinity for the dopamine transporter. Journal of neurochemistry. 1991;56(2):698–701. doi: 10.1111/j.1471-4159.1991.tb08205.x 1988563

13. Katz JL, Terry P, Witkin JM. Comparative behavioral pharmacology and toxicology of cocaine and its ethhanol-derived metabolite, cocaine ethyl-ester (cocaethylene). Life sciences. 1992;50(18):1351–61. doi: 10.1016/0024-3205(92)90286-x 1532847

14. Hearn W, Rose S, Wagner J, Ciarleglio A, Mash D. Cocaethylene is more potent than cocaine in mediating lethality. Pharmacology Biochemistry and Behavior. 1991;39(2):531–3.

15. Wood D, Hunter L, Measham F, Dargan P. Limited use of novel psychoactive substances in South London nightclubs. QJM: An International Journal of Medicine. 2012;105(10):959–64.

16. Iversen L, Gibbons S, Treble R, Setola V, Huang X-P, Roth BL. Neurochemical profiles of some novel psychoactive substances. European journal of pharmacology. 2013;700(1–3):147–51. doi: 10.1016/j.ejphar.2012.12.006 23261499

17. Schifano F, Orsolini L, Duccio Papanti G, Corkery JM. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015;14(1):15–26. doi: 10.1002/wps.20174 25655145

18. Brew I. Novel psychoactive substances. The British Journal of General Practice. 2016;66(644):125.

19. Wikipedia. List of Designer Drugs—Section 7, Synthetic Cannabinoids. online, last accessed 8/2/18, retrieved from https://en.wikipedia.org/wiki/List_of_designer_drugs#Synthetic_cannabinoids: Wikipedia.org; 2018.

20. Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clinical Toxicology. 2016;54(1):1–13. doi: 10.3109/15563650.2015.1110590 26567470

21. Adams AJ, Banister SD, Irizarry L, Trecki J, Schwartz M, Gerona R. “Zombie” outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. New England journal of medicine. 2017;376(3):235–42. doi: 10.1056/NEJMoa1610300 27973993

22. EVERY‐PALMER S. Warning: legal synthetic cannabinoid‐receptor agonists such as JWH‐018 may precipitate psychosis in vulnerable individuals. Addiction. 2010;105(10):1859–60.

23. Peglow S, Buchner J, Briscoe G. Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. The American journal on addictions. 2012;21(3):287–8. doi: 10.1111/j.1521-0391.2012.00222.x 22494236

24. van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. Journal of psychopharmacology. 2015;29(3):254–63. doi: 10.1177/0269881114565142 25586398

25. Al‐Hebshi N, Skaug N. Khat (Catha edulis)—an updated review. Addiction biology. 2005;10(4):299–307. doi: 10.1080/13556210500353020 16318950

26. Brenneisen R, Fisch H, Koelbing U, Geisshusler S, Kalix P. Amphetamine‐like effects in humans of the khat alkaloid cathinone. British journal of clinical pharmacology. 1990;30(6):825–8. doi: 10.1111/j.1365-2125.1990.tb05447.x 2288828

27. Gatherings K. The use of khat (Catha edulis) in Yemen social and medical observations. Annals of internal medicine. 1976;85:246–9. doi: 10.7326/0003-4819-85-2-246 942147

28. Kau G. Flashback to the Federal Analog Act of 1986: Mixing rules and standards in the Cauldron. University of Pennsylvania Law Review. 2008;156(4):1077–115.

29. Perrone D. Chapter 8: Designer drugs. In: Brownstein H, editor. The handbook of drugs and society: Wiley Blackwell, Chichester, UK; 2016. p. 149–75.

30. Sivagnanam K, Chaudari D, Lopez P, Sutherland ME, Ramu VK. “Bath salts” induced severe reversible cardiomyopathy. The American journal of case reports. 2013;14:288. doi: 10.12659/AJCR.889381 23919103

31. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. Journal of Medical Toxicology. 2012;8(1):33–42. doi: 10.1007/s13181-011-0193-z 22108839

32. Carbone PN, Carbone DL, Carstairs SD, Luzi SA. Sudden cardiac death associated with methylone use. The American journal of forensic medicine and pathology. 2013;34(1):26–8. doi: 10.1097/PAF.0b013e31827ab5da 23403480

33. Sacco LN, Finklea KM. Synthetic Drugs: Overview and Issues for Congress Washington, D.C.: Congressional Research Service; 2011.

34. Medrano K. Synthetic Marijuana is a Legal Drug with a Growing Trail of Overdoses and No Studies—Until Now. Newsweek.: Available at: https://www.newsweek.com/synthetic-marijuana-legal-drug-growing-trail-overdoses-and-no-studies-until-719049 Last Accessed 18 April 2019; 2017.

35. Cooney R, van Dorn A. Bad batch: synthetic marijuana overdoses on the rise. The Lancet United States of Health Blog—Available at: https://marlin-prod.literatumonline.com/pb-assets/Lancet/lancet/TL_USA_Posts.pdf Last accessed 18 April 2019; 2018.

36. Palamar JJ, Salomone A, Vincenti M, Cleland CM. Detection of “bath salts” and other novel psychoactive substances in hair samples of ecstasy/MDMA/“Molly” users. Drug and alcohol dependence. 2016;161:200–5. doi: 10.1016/j.drugalcdep.2016.02.001 26883685

37. Perrone D, Helgesen RD, Fischer RG. United States drug prohibition and legal highs: How drug testing may lead cannabis users to Spice. Drugs: education, prevention and policy. 2013;20(3):216–24.

38. McCance-Katz EF, Kosten TR, Jatlow P. Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone—a multiple-dose study. Biological psychiatry. 1998;44(4):250–9. doi: 10.1016/s0006-3223(97)00426-5 9715356

39. Occupati B, Rotulo A, Gori F, Gambassi F, Bertol E, Masini E, editors. Cocaethylene formation following ethanol and cocaine use: a case report. CLINICAL TOXICOLOGY; 2017: TAYLOR & FRANCIS LTD 2–4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON ….

40. Grov C, Kelly BC, Parsons JT. Polydrug use among club-going young adults recruited through time-space sampling. Substance use & misuse. 2009;44(6):848–64.

41. Ramo DE, Grov C, Delucchi KL, Kelly BC, Parsons JT. Cocaine use trajectories of club drug-using young adults recruited using time-space sampling. Addictive behaviors. 2011;36(12):1292–300. doi: 10.1016/j.addbeh.2011.08.003 21907497

42. Walsh DC, Hingson RW, Merrigan DM, Cupples LA, Levenson SM, Coffman GA. Associations between alcohol and cocaine use in a sample of problem-drinking employees. Journal of studies on alcohol. 1991;52(1):17–25. doi: 10.15288/jsa.1991.52.17 1994118

43. Benjamin GA, Darling EJ, Sales B. The prevalence of depression, alcohol abuse, and cocaine abuse among United States lawyers. International Journal of Law and Psychiatry. 1990.

44. Patra J, Fischer B, Maksimowska S, Rehm J. Profiling poly-substance use typologies in a multi-site cohort of illicit opioid and other drug users in Canada–a latent class analysis. Addiction Research & Theory. 2009;17(2):168–85.

45. Connor JP, Gullo MJ, Chan G, Young RM, Hall WD, Feeney GF. Polysubstance use in cannabis users referred for treatment: drug use profiles, psychiatric comorbidity and cannabis-related beliefs. Frontiers in psychiatry. 2013;4:79. doi: 10.3389/fpsyt.2013.00079 23966956

46. Gjersing L, editor TYPOLOGY OF SUBSTANCE USE AMONG A COHORT OF STREET-RECRUITED ILLEGAL POLYSUBSTANCE USERS AND IT’S ASSOCIATION WITH MORTALITY. DRUG AND ALCOHOL REVIEW; 2016: WILEY 111 RIVER ST, HOBOKEN 07030–5774, NJ USA.

47. Substance Abuse and Mental Health Services Administration (SAMHSA). 2016–2017 National Survey on Drug Use and Health: Model-Based Prevalence Estimates (50 States and the District of Columbia). Research Triangle Park, N.C.: Research Triangle International (RTI); 2018.

48. National Institute on Drug Abuse. Opioid Summaries by State. Accessed online: https://www.drugabuse.gov/drugs-abuse/opioids/opioid-summaries-by-state last accessed 24 Oct. 2019; 2019.

49. Elliott L, Benoit E, Campos S, Dunlap E. The long tail of a demon drug: The ‘bath salts’ risk environment. International Journal of Drug Policy. 2018;51:111–6. doi: 10.1016/j.drugpo.2017.10.007 29248872

50. Dunlap E, Graves J, Benoit E. Stages of drug market change during disaster: Hurricane Katrina and reformulation of the New Orleans drug market. International Journal of Drug Policy. 2012;23(6):473–80. doi: 10.1016/j.drugpo.2012.04.003 22728093

51. Cambraia Windsor L, Benoit E, Dunlap E. Dimensions of oppression in the lives of impoverished black women who use drugs. Journal of Black Studies. 2010;41(1):21–39. doi: 10.1177/0021934708326875 21113410

52. Windsor LC, Dunlap E, Armour M. Surviving oppression under the rock: The intersection of new york's drug, welfare, and educational polices in the lived experiences of low-income African Americans. Journal of ethnicity in substance abuse. 2012;11(4):339–61. doi: 10.1080/15332640.2012.735176 23216440

53. Manning C, Raghavan P, Schütze H. Hierarchical clustering. In: Manning C, Raghavan P, Schütze H, editors. An introduction to information retrieval. Cambridge, UK: Cambridge University Press; 2009. p. 377–401.

54. Newcomer SR, Steiner JF, Bayliss EA. Identifying subgroups of complex patients with cluster analysis. The American journal of managed care. 2011;17(8):e324–32. 21851140

55. Fan G, Filipczak L, Chow E. Symptom clusters in cancer patients: a review of the literature. Current oncology. 2007;14(5):173. doi: 10.3747/co.2007.145 17938700

56. Guenther UP, Varon R, Schlicke M, Dutrannoy V, Volk A, Hübner C, et al. Clinical and mutational profile in spinal muscular atrophy with respiratory distress (SMARD): defining novel phenotypes through hierarchical cluster analysis. Human mutation. 2007;28(8):808–15. doi: 10.1002/humu.20525 17431882

57. Cornell JE, Pugh JA, Williams JW Jr, Kazis L, Lee AF, Parchman ML, et al. Multimorbidity clusters: clustering binary data from multimorbidity clusters: clustering binary data from a large administrative medical database. Applied multivariate research. 2008;12(3):163–82.

58. Beckstead JW. Using hierarchical cluster analysis in nursing research. Western Journal of Nursing Research. 2002;24(3):307–19. doi: 10.1177/01939450222045923 11911382

59. Douglass FM, Khavari KA, Farber PD. Three types of extreme drug users identified by a replicated cluster analysis. Journal of abnormal psychology. 1980;89(2):240. doi: 10.1037//0021-843x.89.2.240 7365136

60. Yacoubian GS Jr, Kane RJ. Identifying a drug use typology of Philadelphia arrestees: A cluster analysis. Journal of Drug Issues. 1998;28(2):559–74.

61. Beitchman J, Beitchman JH, Adlaf EM, Douglas L, Atkinson L, Young A, et al. Comorbidity of psychiatric and substance use disorders in late adolescence: A cluster analytic approach. The American journal of drug and alcohol abuse. 2001;27(3):421–40. doi: 10.1081/ada-100104510 11506260

62. Shaw SY, Shah L, Jolly AM, Wylie JL. Identifying heterogeneity among injection drug users: a cluster analysis approach. American Journal of Public Health. 2008;98(8):1430–7. doi: 10.2105/AJPH.2007.120741 18556614

63. Zhang Z, Murtagh F, Van Poucke S, Lin S, Lan P. Hierarchical cluster analysis in clinical research with heterogeneous study population: highlighting its visualization with R. Annals of translational medicine. 2017;5(4).

64. Chavent M, Kuentz V, Liquet B, Saracco J. Package "ClustOfVar' Cran R-Project2017 [cited 2018 23 November]. Available from: https://cran.r-project.org/web/packages/ClustOfVar/ClustOfVar.pdf.

65. Chavent M, Kuentz-Simonet V, Liquet B, Saracco J. ClustOfVar: An R package for the clustering of variables. Journal of Statistical Softward [Internet]. 2012 23 November 2018; 50(13):[1–16 pp.]. Available from: https://www.jstatsoft.org/article/view/v050i13.

66. Galili T, Jefferis G, Gallotta M, al. e. Package "dendextend': Cran R-Project; 2018 [cited 2018 23 November]. Available from: https://cran.r-project.org/web/packages/dendextend/dendextend.pdf.

67. Joseph AM, Manseau MW, Lalane M, Rajparia A, Lewis CF. Characteristics associated with synthetic cannabinoid use among patients treated in a public psychiatric emergency setting. The American journal of drug and alcohol abuse. 2017;43(1):117–22. doi: 10.1080/00952990.2016.1240799 27797288

68. Mars SG, Ondocsin J, Ciccarone D. Toots, tastes and tester shots: user accounts of drug sampling methods for gauging heroin potency. Harm reduction journal. 2018;15(1):26. doi: 10.1186/s12954-018-0232-z 29769132

69. Cameron K, Kolanos R, Verkariya R, De Felice L, Glennon RA. Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of “bath salts,” produce opposite effects at the human dopamine transporter. Psychopharmacology. 2013;227(3):493–9. doi: 10.1007/s00213-013-2967-2 23371489

70. Golub A, Johnson BD. Variation in youthful risks of progression from alcohol and tobacco to marijuana and to hard drugs across generations. American Journal of Public Health. 2001;91(2):225. doi: 10.2105/ajph.91.2.225 11211630

71. Golub A, Johnson BD, Dunlap E. Subcultural evolution and illicit drug use. Addiction research & theory. 2005;13(3):217–29.

72. Degenhardt L, Copeland J, Dillon P. Recent trends in the use of “club drugs”: an Australian review. Substance use & misuse. 2005;40(9–10):1241–56.

73. Pedersen W, Skrondal A. Ecstasy and new patterns of drug use: a normal population study. Addiction. 1999;94(11):1695–706. doi: 10.1046/j.1360-0443.1999.941116957.x 10892008

74. Barrett SP, Gross SR, Garand I, Pihl RO. Patterns of simultaneous polysubstance use in Canadian rave attendees. Substance use & misuse. 2005;40(9–10):1525–37.

75. Touriño C, Zimmer A, Valverde O. THC prevents MDMA neurotoxicity in mice. PLoS One. 2010;5(2):e9143. doi: 10.1371/journal.pone.0009143 20174577

76. Jones CM, Paulozzi LJ, Mack KA. Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse–related emergency department visits and drug-related deaths—united states, 2010. MMWR Morbidity and mortality weekly report. 2014;63(40):881. 25299603


Článek vyšel v časopise

PLOS One


2019 Číslo 12